Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms NJH-05-043 |
Target |
Action antagonists |
Mechanism FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC52H64Cl2N12O8S |
InChIKeyJTSBMXASQWEDHX-PRWMCYMISA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bile Duct Neoplasms | Preclinical | United States | 14 Jun 2021 | |
Bile Duct Neoplasms | Preclinical | United States | 14 Jun 2021 | |
Stomach Cancer | Preclinical | United States | 14 Jun 2021 | |
Stomach Cancer | Preclinical | United States | 14 Jun 2021 |